Raj Reddy
CEO Canary Cure Therapeutics
Raj Reddy is a biotechnology pioneer and the President and CEO of Canary Cure, a leading gene and RNA therapy company developing innovative treatments for metabolic, obesity and rare genetic diseases. With over 10 years of experience scaling biotech ventures and specializing in the endocannabinoid system’s role in metabolic health, Raj brings deep expertise in pharmacology and medicinal chemistry to the company’s groundbreaking work. As the inventor on over 20 patents in genetics and RNA therapy, Raj leads Canary’s development of first-in-class siRNA therapeutics that transform white adipose tissue into energy-burning powerhouses. His flagship innovation, CCT-217, demonstrates unprecedented outcomes in pre-clinical models?achieving 26% weight loss while increasing lean muscle mass by 25%, a stark contrast to current therapies that cause significant muscle deterioration. Raj’s strategic vision combines cutting-edge RNA technology with AI-enhanced personalized approaches to revolutionize treatment paradigms. His previous leadership over a $500 million portfolio has honed his expertise in strategic management and market access. Driven by the transformative potential of genetic medicine, Raj is committed to unlocking new frontiers in precision medicine that enable earlier detection and more effective disease treatment through targeted genetic mechanisms.
Seminars
- Broadening the therapeutic scope of GLP-1s as the new frontier for a wide range of new applications, such as cardiovascular disease, neurodegenerative disorders and ageing, offering patients a more comprehensive approach to health beyond just weight loss
- Enhancing drug delivery for patient success to improve patient adherence through less frequent administration, including once-a-month injections and oral medications, providing a convenient and less intrusive treatment experience that supports longterm adherence
- Integrating a complementary ecosystem of care for collaborative approach of chronic drugs, advanced combinations, and procedural solutions that work together to create a personalized treatment plan for each patient, maximizing chances of achieving sustainable metabolic health
- Moving beyond appetite suppression by leveraging proprietary dual-siRNA technology to target the root genetic drivers of metabolic dysfunction, promoting the ‘browning’ of white fat and significantly enhancing energy expenditure
- Preserving vital lean muscle mass while achieving selective, transformative fat loss, thereby resolving the critical body composition challenges associated with current therapies and securing healthier, more sustainable long-term metabolic outcomes
- Delivering a disruptive, patient-centric treatment option through a targeted genetic approach that offers the potential for infrequent, twice-yearly dosing, fundamentally changing the treatment paradigm and increasing diversity in the next generation of approved drugs
